NATCO Pharma Limited AI Stock Analysis
Want to see IN:NATCOPHARM full AI Analyst Report?
NATCO Pharma Limited (NATCOPHARM) AI Stock Analysis
NATCO Pharma Limited
(NSE:NATCOPHARM)
Robust financials with strong profitability and cash flows are the main drivers. Bearish technical signals from moving averages and MACD present headwinds, while attractive P/E valuation offers support.
NATCO Pharma Limited (NATCOPHARM) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 159.38B
- Dividend Yield
- 0.55%
- Average Volume (3M)
- 42.31K
- Price to Earnings (P/E)
- 12.7
- Beta (1Y)
- 0.83
- Revenue Growth
- -20.73%
- EPS Growth
- -32.59%
- Country
- India
- Employees
- 4,433
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
NATCO Pharma Limited Business Overview & Revenue Model
Company Description
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and intern...
How the Company Makes Money
NATCO Pharma makes money by developing and manufacturing pharmaceutical products and earning revenue from (1) sales of finished dosage formulations (branded generics in India and generic/specialty products in export markets), (2) sales of active phar...
NATCO Pharma Limited Financial Statement Overview
Summary
Strong revenue and profit growth through 2025, low leverage on balance sheet, and improving cash flows, despite potential 2026 revenue decline.
Income Statement
85Very PositiveBalance Sheet
90Very PositiveCash Flow
88Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.85B | 40.78B | 44.32B | 40.02B | 27.09B | 19.46B |
| Gross Profit | 26.53B | 33.88B | 37.05B | 32.53B | 20.54B | 13.62B |
| EBITDA | 12.88B | 17.34B | 21.51B | 17.57B | 9.74B | 2.66B |
| Net Income | 11.44B | 14.19B | 18.85B | 13.88B | 7.15B | 1.70B |
Balance Sheet | ||||||
| Total Assets | 0 | 110.74B | 86.31B | 69.06B | 56.57B | 51.09B |
| Cash, Cash Equivalents and Short-Term Investments | 21.29B | 21.29B | 24.97B | 17.78B | 11.25B | 7.60B |
| Total Debt | 0 | 7.14B | 2.79B | 3.86B | 1.76B | 4.32B |
| Total Liabilities | -92.21B | 18.53B | 10.19B | 10.53B | -34.80B | 8.46B |
| Stockholders Equity | 92.21B | 92.21B | 76.07B | 58.53B | 48.74B | 42.64B |
Cash Flow | ||||||
| Free Cash Flow | 10.10B | 13.77B | 14.28B | 8.72B | 6.43B | -1.96B |
| Operating Cash Flow | 11.91B | 17.68B | 16.97B | 12.12B | 8.49B | 465.00M |
| Investing Cash Flow | -11.89B | -20.82B | -14.14B | -10.33B | -4.77B | -53.00M |
| Financing Cash Flow | -765.00M | 2.98B | -2.11B | -2.47B | -3.63B | 348.00M |
NATCO Pharma Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATCOPHARM, the sentiment is Positive. The current price of 808.80 is above the 20-day moving average (MA) of 792.33, above the 50-day MA of 807.89, and below the 200-day MA of 918.59, indicating a neutral trend. The MACD of -1.94 indicates Negative momentum. The RSI at 55.14 is Neutral, neither overbought nor oversold. The STOCH value of 63.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NATCOPHARM.
NATCO Pharma Limited Peers Comparison
Overall Rating
- IN:NATCOPHARM76Outperform
IN:GRANULES72Outperform
IN:APLLTD71Outperform
IN:STAR65Neutral
IN:WOCKPHARMA57Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:NATCOPHARM | 76Outperform | INR 158.62B | 12.66 | ― | 0.55% | -20.73% | -32.59% |
| IN:GRANULES | 72Outperform | INR 198.14B | 29.08 | ― | 0.21% | 21.75% | 36.70% |
| IN:APLLTD | 71Outperform | INR 202.39B | 24.40 | ― | 1.15% | 19.68% | 33.03% |
| IN:STAR | 65Neutral | INR 92.09B | 15.08 | ― | 0.50% | 11.28% | 55.18% |
| IN:WOCKPHARMA | 57Neutral | INR 330.61B | 81.44 | ― | ― | 25.70% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:NATCOPHARM | NATCO Pharma Limited | 808.80 | 4.48 | 0.56% | |
| IN:APLLTD | Alembic Pharmaceuticals Limited | 1046.80 | 157.24 | 17.68% | |
| IN:GRANULES | Granules India Limited | 840.85 | 295.04 | 54.05% | |
| IN:STAR | Strides Pharma Science Ltd | 1008.00 | 67.20 | 7.14% | |
| IN:WOCKPHARMA | Wockhardt Limited | 2056.35 | 710.05 | 52.74% |
NATCO Pharma Limited Corporate Events
Natco Pharma Publishes Record Date Notice for Upcoming Rights Issue
Natco Pharma Limited has notified the stock exchanges that it has published newspaper notices announcing the record date for its upcoming rights issue in Financial Express and Nava Telangana on September 26, 2026. The company stated that these public...
Natco Pharma Secures Exchange Nod for Rights Issue of Equity Shares
Natco Pharma Limited has received in-principle approvals from the National Stock Exchange of India and BSE for a proposed rights issue of fully paid-up equity shares. The approvals mark a formal step toward launching the capital-raising exercise, whi...
Natco Pharma Plans Investor Meetings in Mumbai and Hong Kong
Natco Pharma has scheduled a series of investor meetings on August 27 and 28, 2026, including an in-person group meeting in Mumbai organised by Nuvama Wealth Management and ICICI Securities. The company will also participate in meetings in Hong Kong...
Natco Pharma Schedules Mumbai Investor Meetings, Affirms No UPSI Disclosure
Natco Pharma has notified the stock exchanges that its officials will participate in an in-person group investor meeting in Mumbai, organized by Nuvama Wealth Management and ICICI Securities, from 19 August 2026 to 21 August 2026. The company stated...
Natco Pharma Publishes Q1 FY27 Results and Announces Interim Dividend
Natco Pharma has published its unaudited financial results for the quarter ended June 30, 2026, in leading newspapers including Business Line, Financial Express, and Nava Telangana. The company also announced an interim dividend for the financial yea...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 02, 2026